NEW YORK–(BUSINESS WIRE)–Viramal, (“the Company”), an emerging specialty pharmaceutical company
developing therapeutics that improve the quality of women’s health,
today announced the appointment of Angela Rossetti to its Board of
Directors, effective immediately.
Ms. Rossetti is a highly qualified corporate director and pharmaceutical
executive who brings more than 20 years’ industry experience to Viramal,
including 10 years senior-level commercialization expertise at
pharmaceutical and biotechnology companies. During the past decade she
has been responsible for the commercialization of both mass market and
rare disease franchises at Pfizer and Wyeth, and hemophilia products at
an early stage biopharmaceutical company, Cell Machines.
Since 2015, Ms. Rossetti has been Executive Vice President and Chief
Commercial Officer at Cell Machines, which is developing
transformational technology for hemophilia and other diseases. From 2009
through 2012, she was a Vice President at Pfizer Inc., where she led a
global commercial medicine team for smoking cessation products. Prior to
that, she was an Assistant Vice President at Wyeth, managing a global
hemophilia franchise from 2007 until 2009, when Wyeth was acquired by
“Angela Rossetti is a seasoned corporate director and pharmaceutical
executive, and we are thrilled to welcome her to Viramal’s Board. Her
commercialization expertise and broad experience across medical,
clinical and regulatory affairs will be instrumental in the progression
of our pipeline
of highly differentiated women’s health products. Angela has a
successful track record of advancing pharmaceutical companies from
inception, through fundraising and commercialization, to expanding the
commercial potential of products. This experience will be invaluable to
Viramal as we develop innovative products that target unmet female
therapeutic areas, as well as produce a step change in existing women’s
healthcare products,” said William Bologna, Viramal’s Chairman.
Ms. Rossetti is currently a director at Palatin Technologies, a
biopharmaceutical company developing targeted, receptor-specific peptide
therapeutics, and MicroHealth, a privately held digital health network
for the hemophilia community. She is an Adjunct Assistant Professor at
New York Medical College. She holds a BA Biology and English from the
University of Pennsylvania, an MBA Finance from Columbia University and
MS Bioethics from the Albert Einstein School of Medicine/Cardozo Law
Viramal recently bolstered its Board of Directors with the appointment
of women’s healthcare expert, William Bologna, as Chairman in February.
Bill Bologna is a pioneer in women’s healthcare who has successfully
developed and licensed market-leading products in fertility and female
Viramal is an emerging specialty pharmaceutical company focused on the
development of therapeutics that improve the quality of women’s health.
The Company’s well-recognized management team has pioneered
market-leading products in fertility and female sexual health, having
successfully developed and licensed Crinone®, Replens® and RepHresh®.
Viramal produces a step change in these existing products, as well as
develops innovative products that target unmet therapeutic areas, by
leveraging novel platform delivery technologies that offer greater
safety, efficacy and patient acceptability with far fewer side effects.
The Company’s robust women’s health clinical development pipeline
includes treatments for fertility, menopausal hormone therapy,
contraception and sexual health. In addition, Viramal’s only male
product, TestoCream (transdermal delivery of testosterone), has shown
81% success in a partially completed Phase III study. Please visit www.viramal.com
for more information.
MBS Value Partners
Buhrer, (212) 661-7004